382 related articles for article (PubMed ID: 30719709)
1. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries.
Vermeulen FM; Gerbens LAA; Bosma AL; Apfelbacher CJ; Irvine AD; Arents BWM; Barbarot S; Deleuran M; Eichenfield LF; Manca A; Schmitt J; Vestergaard C; Wall D; Weidinger S; Middelkamp-Hup MA; Spuls PI; Flohr C;
Br J Dermatol; 2019 Sep; 181(3):492-504. PubMed ID: 30719709
[TBL] [Abstract][Full Text] [Related]
2. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries.
Gerbens LA; Boyce AE; Wall D; Barbarot S; de Booij RJ; Deleuran M; Middelkamp-Hup MA; Roberts A; Vestergaard C; Weidinger S; Apfelbacher CJ; Irvine AD; Schmitt J; Williamson PR; Spuls PI; Flohr C
Trials; 2017 Feb; 18(1):87. PubMed ID: 28241851
[TBL] [Abstract][Full Text] [Related]
3. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries.
Gerbens LAA; Apfelbacher CJ; Irvine AD; Barbarot S; de Booij RJ; Boyce AE; Deleuran M; Eichenfield LF; Hof MH; Middelkamp-Hup MA; Roberts A; Schmitt J; Vestergaard C; Wall D; Weidinger S; Williamson PR; Flohr C; Spuls PI;
Br J Dermatol; 2019 Apr; 180(4):790-801. PubMed ID: 29761486
[TBL] [Abstract][Full Text] [Related]
4. Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce.
Bosma AL; Musters AH; Bloem M; Gerbens LAA; Middelkamp-Hup MA; Haufe E; Schmitt J; Barbarot S; Seneschal J; Staumont-Sallé D; Johansson EK; Bradley M; von Kobyletzki LB; Vittrup I; Frier Ruge I; Thyssen JP; Vestergaard C; de Vega M; García-Doval I; Chiricozzi A; Stingeni L; Calzavara-Pinton P; Ardern-Jones MR; Reynolds NJ; Flohr C; Spuls PI
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):123-136. PubMed ID: 36018221
[TBL] [Abstract][Full Text] [Related]
5. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.
Bosma AL; Spuls PI; Garcia-Doval I; Naldi L; Prieto-Merino D; Tesch F; Apfelbacher CJ; Arents BWM; Barbarot S; Baselga E; Deleuran M; Eichenfield LF; Gerbens LAA; Irvine AD; Manca A; Mendes-Bastos P; Middelkamp-Hup MA; Roberts A; Seneschal J; Svensson Å; Thyssen JP; Torres T; Vermeulen FM; Vestergaard C; von Kobyletzki LB; Wall D; Weidinger S; Schmitt J; Flohr C
Br J Dermatol; 2020 Jun; 182(6):1423-1429. PubMed ID: 31444799
[TBL] [Abstract][Full Text] [Related]
6. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2021 Jul; 185(1):139-146. PubMed ID: 33393074
[TBL] [Abstract][Full Text] [Related]
7. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).
Chalmers JR; Simpson E; Apfelbacher CJ; Thomas KS; von Kobyletzki L; Schmitt J; Singh JA; Svensson Å; Williams HC; Abuabara K; Aoki V; Ardeleanu M; Awici-Rasmussen M; Barbarot S; Berents TL; Block J; Bragg A; Burton T; Bjerring Clemmensen KK; Creswell-Melville A; Dinesen M; Drucker A; Eckert L; Flohr C; Garg M; Gerbens LA; Graff AL; Hanifin J; Heinl D; Humphreys R; Ishii HA; Kataoka Y; Leshem YA; Marquort B; Massuel MA; Merhand S; Mizutani H; Murota H; Murrell DF; Nakahara T; Nasr I; Nograles K; Ohya Y; Osterloh I; Pander J; Prinsen C; Purkins L; Ridd M; Sach T; Schuttelaar ML; Shindo S; Smirnova J; Sulzer A; Synnøve Gjerde E; Takaoka R; Vestby Talmo H; Tauber M; Torchet F; Volke A; Wahlgren CF; Weidinger S; Weisshaar E; Wollenberg A; Yamaga K; Zhao CY; Spuls PI
Br J Dermatol; 2016 Jul; 175(1):69-79. PubMed ID: 27436240
[TBL] [Abstract][Full Text] [Related]
8. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries.
Spuls PI; Gerbens LAA; Apfelbacher CJ; Wall D; Arents BWM; Barbarot S; Roberts A; Deleuran M; Middelkamp-Hup MA; Vestergaard C; Weidinger S; Schmitt J; Irvine AD; Flohr C
J Invest Dermatol; 2017 Sep; 137(9):2014-2016. PubMed ID: 28558913
[No Abstract] [Full Text] [Related]
9. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.
Schmitt J; Spuls PI; Thomas KS; Simpson E; Furue M; Deckert S; Dohil M; Apfelbacher C; Singh JA; Chalmers J; Williams HC;
J Allergy Clin Immunol; 2014 Oct; 134(4):800-7. PubMed ID: 25282560
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review.
Gerbens LA; Prinsen CA; Chalmers JR; Drucker AM; von Kobyletzki LB; Limpens J; Nankervis H; Svensson Å; Terwee CB; Zhang J; Apfelbacher CJ; Spuls PI;
Allergy; 2017 Jan; 72(1):146-163. PubMed ID: 27322918
[TBL] [Abstract][Full Text] [Related]
11. What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 3: nomenclature and outcome assessment.
Lloyd-Lavery A; Solman L; Grindlay DJC; Rogers NK; Thomas KS; Harman KE
Clin Exp Dermatol; 2019 Jun; 44(4):376-380. PubMed ID: 30706507
[TBL] [Abstract][Full Text] [Related]
12. Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.
Leshem YA; Chalmers JR; Apfelbacher C; Katoh N; Gerbens LAA; Schmitt J; Spuls PI; Thomas KS; Howells L; Williams HC; Simpson EL;
JAMA Dermatol; 2022 Dec; 158(12):1429-1435. PubMed ID: 36223090
[TBL] [Abstract][Full Text] [Related]
13. The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema.
Vermeulen FM; Gerbens LAA; Schmitt J; Deleuran M; Irvine AD; Logan K; Ouwerkerk W; Vestergaard C; Flohr C; Spuls PI;
Br J Dermatol; 2020 Dec; 183(6):1073-1082. PubMed ID: 32068893
[TBL] [Abstract][Full Text] [Related]
14. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.
Spuls PI; Gerbens LAA; Simpson E; Apfelbacher CJ; Chalmers JR; Thomas KS; Prinsen CAC; von Kobyletzki LB; Singh JA; Williams HC; Schmitt J;
Br J Dermatol; 2017 Apr; 176(4):979-984. PubMed ID: 27858989
[TBL] [Abstract][Full Text] [Related]
15. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative.
Leshem YA; Chalmers JR; Apfelbacher C; Furue M; Gerbens LAA; Prinsen CAC; Schmitt J; Spuls PI; Thomas KS; Williams HC; Simpson EL;
J Am Acad Dermatol; 2020 May; 82(5):1181-1186. PubMed ID: 31926221
[TBL] [Abstract][Full Text] [Related]
16. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2020 Nov; ():. PubMed ID: 33179283
[TBL] [Abstract][Full Text] [Related]
17. [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany].
Haufe E; Abraham S; Heratizadeh A; Harder I; Zink A; Weisshaar E; Kleinheinz A; von Kiedrowski R; Worm M; Bell M; Wollenberg A; Neubert K; Staubach-Renz P; Hilgers M; Bieber T; Fell I; Homey B; Effendy I; Mempel M; Schäkel K; Beissert S; Weidinger S; Werfel T; Schmitt J
Hautarzt; 2018 Oct; 69(10):815-824. PubMed ID: 30191254
[TBL] [Abstract][Full Text] [Related]
18. What's in a name? Atopic dermatitis or atopic eczema, but not eczema alone.
Silverberg JI; Thyssen JP; Paller AS; Drucker AM; Wollenberg A; Lee KH; Kabashima K; Todd G; Schmid-Grendelmeier P; Bieber T
Allergy; 2017 Dec; 72(12):2026-2030. PubMed ID: 28605026
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice.
van Geel N; Hamzavi IH; Pandya AG; Wolkerstorfer A; Seneschal J; Garg A; Spuls P; Terwee CB; Mallett S; Speeckaert R; Meurant JM; Eleftheriadou V; Ezzedine K
Trials; 2022 Jul; 23(1):591. PubMed ID: 35871019
[TBL] [Abstract][Full Text] [Related]
20. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting.
Schmitt J; Spuls P; Boers M; Thomas K; Chalmers J; Roekevisch E; Schram M; Allsopp R; Aoki V; Apfelbacher C; Bruijnzeel-Koomen C; Bruin-Weller M; Charman C; Cohen A; Dohil M; Flohr C; Furue M; Gieler U; Hooft L; Humphreys R; Ishii HA; Katayama I; Kouwenhoven W; Langan S; Lewis-Jones S; Merhand S; Murota H; Murrell DF; Nankervis H; Ohya Y; Oranje A; Otsuka H; Paul C; Rosenbluth Y; Saeki H; Schuttelaar ML; Stalder JF; Svensson A; Takaoka R; Wahlgren CF; Weidinger S; Wollenberg A; Williams H
Allergy; 2012 Sep; 67(9):1111-7. PubMed ID: 22844983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
